3dGRO^® Human Liver Organoids (MNFBQ01LI(47-49))

Patient derived organoids (PDOs) are novel in vitro 3D cell models that have tissue-like functionality and are an alternative to traditional 2D cell lines and PDX animal models 1,2. PDOs can be derived from adult patient biopsies or resected tissues containing native LGR5+ stem cell populations and cultured within an ECM-rich substrate using specialized organoid media 3. Adult tissue derived organoids are thought to have more mature phenotypes than iPSC derived organoids and have been shown to predict patient responses to chemotherapeutics 4.
MilliporeSigma′s 3dGRO^® normal liver organoid biobank is a collection of tissue-derived normal, undiseased human liver organoids. The normal liver organoid biobank contains highly characterized organoid lines from healthy donors. The 3DGRO® normal liver organoid biobank consists of Immature Liver Organoids (ILO) which can be thawed, passaged and banked back. The ILO express markers for both hepatocytes and cholangiocytes, and when needed, they may be differentiated into Mature Liver Organoids (MLO), which are terminally differentiated.

Patient Specific Details
Organ Type: Liver
Patient Age: 50 years
Patient Species: Human
Sex: Female
Race: Asian Pacific
Disease: Normal
Tumor Source: Non-Tumor
Model ID: MNFBQ01LI47

Specifications
Viability: >1500 organoids/vial
Organoid Growth: The organoids can be cultured for at least 5 passages after initial thawing without significantly affecting the cell marker expression and functionality.
Species Verification: Species has been verified and confirmed to be negative for inter-species contamination by a Contamination Clear panel by Charles River Animal Diagnostic Services.

• Infectious Disease Testing: Cells tested negative for infectious disease by a PCR panel. Human lines negative for HPV-16, HPV-18, Hepatitis A, B, C, and HIV-1 & 2 viruses.
• Microbial Contamination: None detected.
• Mycoplasma Contamination: Negative
• STR Profile: Pass
• Characterization: Immunocytochemistry

These organoids should be stored in liquid nitrogen.

Yang H, Sun L, Liu M, Mao Y. 2018. Patient-derived organoids: a promising model for personalized cancer treatment Gastroenterol Rep (Oxf). 6(4):243–245.Margit Bleijs M, van de Wetering M, Clevers H, Drost J. 2019. Xenograft and organoid model systems in cancer research. EMBO J. 38(15):e101654.Broutier L, Andersson-Rolf A, Hindley CJ, Boj SF, Clevers H, Koo B, Huch M. 2016. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat. Protoc. 11(9):1724-43.Harrison SP, Baumgarten SP, Verma R, Oleg Lunov O, Dejneka A, Sullivan GJ. 2021. Liver Organoids: Recent Developments, Limitations and Potential. Front. Med. (Lausanne). 8:574047

3dGRO^® is a trademark of Merck KGaA, Darmstadt, Germany.
3dGRO^® organoids were derived utilizing HUB Organoid Technology.

Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/pdouse. This product may not be re-engineered or copied; used to make derivatives or modifications; used to develop, test, or manufacture a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact organoids@milliporesigma.com.

3dGRO is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.